1. Home
  2. OMER vs TRST Comparison

OMER vs TRST Comparison

Compare OMER & TRST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • TRST
  • Stock Information
  • Founded
  • OMER 1994
  • TRST 1902
  • Country
  • OMER United States
  • TRST United States
  • Employees
  • OMER N/A
  • TRST N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • TRST Major Banks
  • Sector
  • OMER Health Care
  • TRST Finance
  • Exchange
  • OMER Nasdaq
  • TRST Nasdaq
  • Market Cap
  • OMER 532.0M
  • TRST 624.8M
  • IPO Year
  • OMER 2009
  • TRST N/A
  • Fundamental
  • Price
  • OMER $9.18
  • TRST $32.75
  • Analyst Decision
  • OMER Buy
  • TRST
  • Analyst Count
  • OMER 4
  • TRST 0
  • Target Price
  • OMER $22.50
  • TRST N/A
  • AVG Volume (30 Days)
  • OMER 422.2K
  • TRST 71.6K
  • Earning Date
  • OMER 03-31-2025
  • TRST 01-21-2025
  • Dividend Yield
  • OMER N/A
  • TRST 4.34%
  • EPS Growth
  • OMER N/A
  • TRST N/A
  • EPS
  • OMER N/A
  • TRST 2.57
  • Revenue
  • OMER N/A
  • TRST $169,773,000.00
  • Revenue This Year
  • OMER N/A
  • TRST N/A
  • Revenue Next Year
  • OMER N/A
  • TRST N/A
  • P/E Ratio
  • OMER N/A
  • TRST $12.92
  • Revenue Growth
  • OMER N/A
  • TRST N/A
  • 52 Week Low
  • OMER $2.61
  • TRST $25.83
  • 52 Week High
  • OMER $13.60
  • TRST $38.89
  • Technical
  • Relative Strength Index (RSI)
  • OMER 51.19
  • TRST 47.33
  • Support Level
  • OMER $9.06
  • TRST $32.46
  • Resistance Level
  • OMER $9.43
  • TRST $34.20
  • Average True Range (ATR)
  • OMER 0.52
  • TRST 1.06
  • MACD
  • OMER 0.08
  • TRST 0.06
  • Stochastic Oscillator
  • OMER 52.25
  • TRST 47.57

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About TRST TrustCo Bank Corp NY

Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The Company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey and Vermont.

Share on Social Networks: